

Sprycel[®] (dasatinib) – First-time generic

- On September 1, 2024, [Apotex launched](#) an [AB-rated](#) generic version of Bristol Myers Squibb's [Sprycel \(dasatinib\)](#) tablets.
 - Apotex has been granted [180 days of generic exclusivity](#) for its generic Sprycel.
- Sprycel is approved for the treatment of adult patients with:
 - Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
 - Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib
 - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
- Sprycel is also approved for the treatment of pediatric patients 1 year of age and older with:
 - Ph+ CML in chronic phase
 - Newly diagnosed Ph+ ALL in combination with chemotherapy.